Loading…
Loading…
PMI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PMI and 80,000+ other tickers.
See exactly how PMI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PMI and 80,000+ other tickers.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary duties to shareholders.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Picard (PMI) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Picard between September 2, 2025, and October 31, 2025 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the world's first and only total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the second quarter ended June 30, 2026.
/C O R R E C T I O N -- Fundstrat Capital/ PR Newswire NEW YORK, June 9, 2026 In the
/C O R R E C T I O N -- Fundstrat Capital/ PR Newswire NEW YORK, June 3, 2026 In the